Can Cosentyx (secukinumab) be used with live vaccines?
Cosentyx (secukinumab), an IL-17A inhibitor, can weaken parts of the immune response. Because of that, live vaccines are generally a concern during treatment with biologic immunomodulators like Cosentyx. The key risk is that a live vaccine could replicate in the body more than it would in someone with a normal immune system, potentially causing vaccine-related infection rather than safe immunity.
What specific risk is live vaccination associated with?
The main risk is infection from the vaccine strain. Live vaccines contain weakened (but living) organisms. If IL-17A blockade reduces the body’s ability to contain these organisms, the live vaccine could lead to illness instead of providing protection.
What do patients typically need to do before starting Cosentyx?
A common practical approach is to avoid live vaccines during therapy and to bring needed vaccinations up to date before starting Cosentyx. That way, live vaccines (if they are appropriate for the person) can be given when the immune system is not being suppressed by the drug.
What if someone already got a live vaccine while on Cosentyx?
If a live vaccine is given during treatment, the patient should contact their clinician to assess the situation. Clinicians may monitor for symptoms of infection and decide whether any additional steps are needed. The risk can vary by vaccine type, patient health, and how long the patient has been taking Cosentyx, but the underlying concern is vaccine-related infection.
Does this apply to all vaccines, or only live ones?
This concern is specific to live vaccines. Inactivated (non-live) vaccines do not contain replicating organisms, so they do not carry the same risk of vaccine-strain infection. However, effectiveness can still be lower with some immunomodulators, so clinicians often tailor immunization plans to the individual.
How do timing and drug duration affect vaccine risk?
The risk is highest while Cosentyx is actively suppressing immune signaling. Because biologics like secukinumab can persist in the body for some time, clinicians often consider timing around dosing when planning vaccinations, especially for live vaccines.
Are there alternatives for protection if live vaccines are avoided?
If a live vaccine is typically used for prevention but is not appropriate during Cosentyx therapy, clinicians may use non-live alternatives when available (or adjust the vaccination schedule until it’s safe). For many routine immunizations, non-live options exist, but the best choice depends on age, local guidelines, and the exact vaccine being considered.
Sources
- Cosentyx (secukinumab) prescribing information – Vaccinations / live vaccines precautions